NJ Overdose Dashboard and SUDORS Data

New Jersey publishes overdose surveillance data through two primary systems: the NJ Department of Health’s overdose dashboard and participation in the CDC’s State Unintentional Drug Overdose Reporting System (SUDORS). Together, these tools provide the most comprehensive publicly available picture of drug overdose trends in the state — by county, substance, demographics, and time.

Understanding this data matters. For families, it provides context on the risk landscape. For researchers and advocates, it supports evidence-based policy recommendations. For treatment providers, it informs program design and resource allocation. This page explains what each data source captures, how to access and interpret the information, and what the data currently shows about New Jersey’s overdose crisis.

Key Takeaways

• The NJ Department of Health maintains an overdose dashboard tracking suspected and confirmed drug-related deaths by county, substance, and demographics.
• SUDORS (State Unintentional Drug Overdose Reporting System) is a CDC-funded program that provides more detailed data than vital statistics alone, including toxicology findings and circumstances of death.
• Fentanyl is involved in the majority of NJ overdose deaths and has been the primary driver of mortality increases.
• County-level disparities are significant: Essex, Camden, Ocean, and Passaic counties have consistently reported among the highest death totals.
• The data has inherent lag times — the dashboard tracks suspected deaths in near-real-time, but confirmed data may lag by months.

What Is the NJ Overdose Dashboard?

How the Dashboard Works

The NJ Department of Health publishes an interactive overdose dashboard that tracks drug-related deaths across the state. The dashboard is part of New Jersey’s broader effort to use real-time data to inform public health response to the overdose crisis.

What the dashboard tracks:

• Suspected drug-related deaths: Reported by medical examiners and law enforcement in near-real-time. These are cases where drug overdose is the suspected cause of death but toxicology results are not yet available.
• Confirmed drug-related deaths: Deaths where toxicology testing has confirmed the involvement of specific substances. Confirmation can lag weeks to months behind the suspected death report.
• Geographic distribution: Data is broken down by county, allowing users to see which areas of the state are most affected.
• Substance involvement: The dashboard identifies which drugs are detected in confirmed cases, including opioids (fentanyl, heroin, prescription opioids), cocaine, benzodiazepines, methamphetamine, and alcohol.
• Demographic information: Available data includes age, gender, and race/ethnicity breakdowns.

The dashboard is updated regularly, though the frequency can vary. Users should note the “last updated” date when interpreting the data.

Data Sources and Methodology

The overdose dashboard draws from multiple data sources:

• NJ Office of the Chief State Medical Examiner (OCSME): Provides confirmed cause-of-death data based on autopsy and toxicology results. This is the gold standard data source but has the longest lag time.
• County medical examiner reports: Initial suspected death reports come from county medical examiners and coroners, providing near-real-time awareness of potential overdose deaths.
• Emergency department syndromic surveillance: Some dashboard components incorporate ED visit data for overdose-related presentations, providing a broader picture of non-fatal overdose events.

Limitations to understand:

• Lag time: Suspected deaths are reported quickly, but confirmed data may not be available for months. This means the most recent data on the dashboard is likely an undercount.
• Polysubstance detection: Many overdose deaths involve multiple substances. A single death may be counted under multiple substance categories, making it inaccurate to simply add up substance-specific numbers to get a total.
• Classification challenges: Determining whether a death is drug-related requires medical examiner judgment. Cases involving medical conditions, accidents, or unclear circumstances may be classified differently across jurisdictions.

Understanding SUDORS

What SUDORS Is

The State Unintentional Drug Overdose Reporting System (SUDORS) is a surveillance system funded by the CDC as part of the Overdose Data to Action (OD2A) program. SUDORS collects detailed information on unintentional and undetermined intent drug overdose deaths, going beyond what standard vital statistics capture.

What makes SUDORS different from standard death certificate data:

• Detailed toxicology: SUDORS captures specific substances found on toxicology testing, including novel psychoactive substances that may not appear on standard drug panels.
• Circumstances of death: SUDORS records information about the setting, witnesses, naloxone administration, history of substance use treatment, and other contextual factors.
• Route of administration: When determinable, SUDORS captures how the drug was used (injection, inhalation, oral).
• Treatment history: SUDORS data includes information about whether the deceased had a history of substance use treatment, which informs understanding of treatment gaps.

How NJ Participates

New Jersey is a SUDORS participating state, meaning that the state’s medical examiner system contributes detailed abstraction data to the CDC’s national database. The NJ OCSME works with the NJ Department of Health to abstract information from death investigation files, toxicology reports, and scene investigation reports for each qualifying death.

NJ’s participation in SUDORS means that:

• Researchers and health officials can compare NJ’s overdose patterns to national trends and other participating states.
• More granular data is available for NJ than would be accessible through vital statistics alone.
• CDC provides funding and technical assistance to support NJ’s overdose surveillance capacity.

SUDORS data is typically published in CDC reports and through the CDC WONDER database, though there is a significant lag between the date of death and data availability (often 12 to 18 months).

Key Trends in NJ Overdose Data

Fentanyl’s Dominance in Overdose Deaths

Fentanyl has transformed New Jersey’s overdose landscape. According to OCSME data, fentanyl and fentanyl analogs are now involved in the majority of confirmed drug-related deaths in the state. This represents a dramatic shift from the earlier phases of the opioid crisis, when prescription opioids and heroin were the primary drivers.

Key aspects of fentanyl’s impact in NJ:

• Potency: Fentanyl is roughly 50 to 100 times more potent than morphine. The margin between a dose that produces the desired effect and a lethal dose is extremely narrow.
• Supply contamination: Fentanyl has been detected not only in heroin but also in cocaine, counterfeit prescription pills, and methamphetamine. Individuals who do not believe they are using opioids may be unknowingly exposed.
• Xylazine: In recent years, NJ has detected the veterinary tranquilizer xylazine mixed with fentanyl in an increasing proportion of overdose deaths. Xylazine complicates overdose response because it does not respond to naloxone.

County-Level Disparities

Overdose mortality is not evenly distributed across New Jersey. According to the NJ overdose dashboard:

• Essex County (Newark) consistently reports among the highest raw totals, driven by the county’s large population and concentrated urban poverty.
• Camden County reports elevated numbers reflecting Camden city’s drug market dynamics and high-poverty population.
• Ocean County has reported among the highest per-capita rates, reflecting the severe opioid crisis along the Shore corridor.
• Passaic County (Paterson) reports significant mortality driven by urban substance use patterns.
• Monmouth and Middlesex counties report high raw numbers consistent with their large suburban populations.

Rural counties (Sussex, Warren, Salem) report lower raw numbers but may have elevated per-capita rates, reflecting limited treatment access and the rural opioid crisis dynamic.

Demographic Patterns

NJ overdose data reveals important demographic patterns:

• Age: The highest concentration of overdose deaths occurs among adults aged 25 to 54, with the 35-to-44 age group often reporting the highest numbers.
• Gender: Males account for a significantly larger proportion of overdose deaths than females, consistent with national patterns.
• Race and ethnicity: Overdose mortality rates have risen across all racial and ethnic groups in NJ. In recent years, increases among Black and Hispanic/Latino populations have been particularly notable, closing what was previously a gap with non-Hispanic White populations.

These demographic patterns inform treatment planning and outreach efforts. Programs that serve the populations most affected by overdose mortality need adequate funding and culturally responsive services.

How to Use This Data

For Families and Individuals

For families and individuals affected by addiction, the overdose dashboard and SUDORS data provide important context:

• Understanding local risk: Knowing which substances are most dangerous in your area helps inform harm reduction decisions. If fentanyl is dominant in your county’s overdose deaths, naloxone (Narcan) availability becomes critical.
• Evaluating treatment urgency: County-level death data can underscore the seriousness of the local crisis and motivate treatment engagement. This is factual context, not fearmongering — the data speaks for itself.
• Accessing naloxone: NJ provides free naloxone through many pharmacies, harm reduction organizations, and county health departments. Knowing the overdose risk in your area strengthens the case for having naloxone available.

For Researchers and Policy Advocates

The NJ overdose dashboard and SUDORS data are essential tools for evidence-based advocacy:

• Resource allocation: County-level data can support arguments for directing treatment funding, naloxone distribution, and harm reduction services to the most affected areas.
• Program evaluation: Tracking overdose trends over time allows assessment of whether state and county interventions are having measurable impact.
• Policy development: Data on specific substances (fentanyl, xylazine), demographics, and circumstances of death inform policy recommendations around prescribing guidelines, drug scheduling, harm reduction legality, and treatment access expansion.

How to navigate the dashboard:

1. Access the NJ Department of Health overdose dashboard through the NJ DOH website.
2. Select the geographic level (statewide or county-specific).
3. Select the time period of interest.
4. Review both suspected and confirmed data, noting the lag time for confirmed figures.
5. For substance-specific data, remember that polysubstance involvement means numbers may overlap.

For SUDORS-specific data, the CDC’s WONDER database and published CDC reports provide access, though with a longer data lag.

Dashboard Walkthrough: Finding Specific Answers in the NJ Data

The NJ overdose dashboard is not one tool — it’s a layered interface with multiple views, filters, and lag patterns. For a reader who clicks through the NJ DOH or NJ CARES dashboard cold, the interface is often more confusing than informative. This walkthrough covers how to find answers to the specific questions families, researchers, and advocates most commonly ask.

Question: How many people died of overdose in my county last year?

Start with the NJ CARES Suspected Overdose Deaths Dashboard (operated by the NJ Attorney General’s Office, njoag.gov). This is the weekly-updated view with the most current data. Filter by county and by year. Note: the number you see is suspected deaths, not toxicologically confirmed — the confirmed number (from OCSME) will lag by 9-18 months and is usually 5-10% lower after investigation resolves ambiguous cases. For most advocacy and awareness purposes, the suspected-deaths number is what you want to cite, with the “suspected” caveat noted.

Question: Which specific substances drove deaths in my county?

The substance-breakdown data is on the NJ DOH overdose mortality dashboard, which draws from OCSME confirmed data. Select the county, then the time period, then view the substance involvement panel. Important interpretive note: because most overdose deaths involve multiple substances (particularly fentanyl combined with cocaine, benzodiazepines, or xylazine), the substance-specific percentages add up to more than 100%. Don’t treat them as mutually exclusive categories — a single death can contribute to fentanyl + cocaine + xylazine counts simultaneously.

Question: How has the pattern changed over 3-5 years?

Time-series views are available on both the NJ DOH dashboard and NJ CARES. Select the longest time range available. Two interpretation cautions: (a) methodology revisions can create apparent discontinuities that are really reporting artifacts rather than real changes — look for footnotes on methodology updates, and (b) the most recent year’s data is almost always incomplete (toxicology confirmations still coming in), so “last year looks like a decline” may be an artifact of incomplete reporting. Only compare fully-reported years when drawing trend conclusions.

Question: Are specific demographics disproportionately affected?

Demographic breakdowns on the NJ DOH dashboard cover age, gender, and race/ethnicity. The race/ethnicity data is particularly important: overdose deaths among Black and Hispanic/Latino populations have risen at higher rates than among non-Hispanic White populations over recent years. Historical assumptions about overdose as a “white problem” no longer hold. Advocates making the case for culturally responsive treatment expansion can cite these demographic shifts directly from the dashboard.

Question: Is the crisis getting better or worse?

This is the hardest question to answer from the dashboard alone. Absolute death counts have declined modestly from the 2021 peak, but: (a) fentanyl saturation has stabilized the baseline at historically elevated levels, (b) polysubstance patterns with xylazine add complications that death counts alone don’t capture, and (c) the decline may be partially attributable to successful harm reduction and MAT expansion rather than an organic shift. The honest answer for advocacy purposes is: “Deaths have declined from the peak but remain substantially elevated; the crisis shape is shifting, not ending.” The NJ DOH has published retrospective analyses that contextualize year-over-year changes — link to these rather than making bare year-to-year comparisons.

Common interpretation mistakes to avoid:

1. Adding suspected and confirmed numbers together. They are the same deaths counted in different reporting streams, not additive.
2. Comparing the current year to a fully-reported prior year without adjusting for lag. The current year is almost always undercounted because toxicology confirmations are still coming in.
3. Treating county-level per-capita rates for small counties as precise. Counties with under 50 annual overdose deaths have high year-to-year variability driven by small numbers; per-capita rates can shift dramatically with just a few cases.
4. Drawing substance-specific conclusions from polysubstance overlapping categories. A “40% fentanyl involvement” finding doesn’t mean 40% of deaths were fentanyl-only.
5. Using dashboard data to compare NJ to other states. State-level differences in reporting practices, medical examiner standards, and toxicology capabilities make cross-state comparisons unreliable. Use CDC WONDER for state-to-state comparisons instead.

---

What SUDORS Data Reveals That Death Counts Don’t

Standard vital statistics tell you that someone died and what substances were found in their system. SUDORS goes several layers deeper — collecting circumstance, context, and pattern data that reshape how advocates, researchers, and treatment providers understand the overdose crisis. For a NJ-focused user of this data, knowing what SUDORS adds (and what you’d miss if you relied only on death certificates) is where the defensibility of advocacy arguments comes from.

Xylazine detection and geographic penetration. SUDORS captures xylazine involvement in overdose deaths — detection that doesn’t appear on standard opioid panels. NJ SUDORS data has been tracking xylazine prevalence in NJ overdose deaths at increasing rates over recent years, with particular concentration in urban and shore-corridor counties. Standard death certificates classify these as “fentanyl overdose” because the fentanyl was the primary agent, obscuring the xylazine role in wound complications, altered presentation, and naloxone non-response. SUDORS reveals the xylazine contamination story that death counts alone hide.

Bystander presence at scene. SUDORS records whether another person was present at the time of overdose. The data has consistently shown that a substantial fraction of NJ overdose deaths occur with someone nearby — a housemate, partner, friend, or family member. This reshapes harm reduction strategy: if someone is typically present, broad naloxone distribution to that population has high leverage. Death counts alone don’t tell you the person wasn’t alone.

Naloxone administration before death. SUDORS records whether naloxone was administered during the overdose event. When naloxone was given but the person still died, that’s a specific scenario — either the fentanyl dose overwhelmed the naloxone dose (common with high-potency analogs), or xylazine’s non-opioid respiratory depression continued after naloxone reversed the opioid component, or additional doses were needed and not available. NJ SUDORS data showing naloxone-administered-but-died cases supports policy arguments for multi-dose naloxone distribution (2+ doses per kit) and wider availability.

Treatment history of decedents. SUDORS captures whether the person had known substance use treatment history, including timing of last treatment. Many NJ overdose deaths occur in people with recent treatment episodes, most commonly in the weeks following a residential discharge or a period of incarceration (both being tolerance-reduced windows). This data supports the case for post-discharge naloxone distribution, warm-handoff aftercare protocols, and MAT continuity across transitions — arguments that “overdose deaths” as a category doesn’t reveal on its own.

Route of administration. When determinable, SUDORS records how the drug was used (injection, smoking/inhalation, oral, insufflation). Route patterns have shifted meaningfully — smoking fentanyl has become more common than injection in recent years in many markets, changing the harm-reduction intervention mix (test strips, supply-of-use paraphernalia, safer-smoking kits). Death certificates don’t capture this shift.

Location of death. SUDORS categorizes location (home, hotel/motel, treatment facility, public place, etc.). Home is the most common location — which matters for naloxone distribution priorities (family members in the home are the highest-leverage distribution target) and for the policy framing around “addiction as public disorder,” which the data does not support: most deaths happen in residences, not in public spaces.

Concurrent mental health diagnoses. SUDORS abstracts mental health treatment history from decedent records when available. NJ data consistently shows high rates of co-occurring mental health diagnoses among overdose decedents, reinforcing the case for integrated dual diagnosis treatment (see mental health and dual diagnosis). Standard death records don’t capture this link.

Known prior nonfatal overdose. SUDORS captures prior overdose history. The data shows that a substantial fraction of fatal overdose decedents had a prior nonfatal overdose — often in the year preceding death. This supports the case for aggressive post-nonfatal-overdose intervention (see the post-overdose window section of opioid addiction): prior nonfatal overdoses are among the strongest predictors of fatal overdose.

The practical effect for NJ advocacy. Arguments grounded in SUDORS data (xylazine contamination, bystander presence, prior nonfatal overdose as predictor, MAT-discharge-window mortality) carry weight in legislative and funding conversations in ways that death totals alone don’t. A budget request for naloxone distribution backed by “X% of NJ overdoses had a bystander present; Y% had a prior nonfatal event in the past 12 months” is fundamentally more actionable than a budget request backed by “Z people died last year.”

---

Using This Data for Advocacy, Grants, and Programmatic Arguments

The NJ overdose dashboard and SUDORS aren’t just reference material — they’re source data for every well-grounded NJ advocacy argument, every competitive grant application, and every program design conversation happening in the NJ behavioral-health ecosystem. How the data is presented in any of those contexts determines whether arguments land. This section is how to use it well.

For county-level grant applications. Programs applying for county-administered opioid settlement funds, SAMHSA Block Grant sub-allocations, or HRSA Rural Health grants routinely need data showing local overdose impact. Specific moves that strengthen applications:

• Cite the NJ CARES dashboard as source, with access date (the dashboard updates weekly, so referring to “as of [date]” provides currency)
• Include a 3-5 year trend chart from the county-level dashboard to show sustained need, not just a single year’s snapshot
• Incorporate SUDORS-based detail (xylazine, naloxone-administered cases, prior nonfatal overdoses) to demonstrate analytical depth beyond death-count basics
• Compare county rate to statewide average to show relative impact
• For any demographic-specific programming, cite the dashboard’s demographic breakdown showing impact on the target population

For legislative and policy advocacy. Arguments to NJ legislators, county freeholders, or state agency decision-makers benefit from:

• Recent, specific data (last quarter or last year) rather than older aggregate figures
• Year-over-year change framed honestly — “declined from peak but remains X% above pre-crisis baseline” rather than cherry-picking the direction
• Demographic-specific data when advocating for population-specific programs
• SUDORS-derived context — specifically the post-treatment-window overdose pattern is a strong argument for continuity-of-care funding
• Connection to specific policy levers — naloxone distribution funding, SAP expansion, MAT access, Drug Court expansion

For treatment program design. Programs designing new services, adjusting existing programming, or choosing geographic placement use the data to:

• Identify county-level service gaps (high overdose impact + low treatment capacity = programming opportunity)
• Target outreach to specific demographics showing rising mortality
• Design post-discharge protocols aligned with the tolerance-reduction mortality pattern SUDORS reveals
• Incorporate harm reduction (naloxone, test strips) in contexts where SUDORS shows the supply contamination pattern (xylazine, fentanyl-in-stimulant contamination)

Citation conventions. When using NJ overdose data in any formal writing (grants, policy memos, academic work, media), standard citation practice:

• NJ CARES Suspected Overdose Deaths Dashboard — njoag.gov/programs/nj-cares (access date)
• NJ Department of Health Overdose Data Dashboard — nj.gov/health (access date)
• SUDORS data via CDC — CDC’s Overdose Data to Action program, with the NJ data-abstraction note
• OCSME confirmed data — NJ Office of the Chief State Medical Examiner, referenced through the NJ DOH dashboard or published NJ OCSME annual reports
• NJ DHS addiction admissions data — NJ Substance Abuse Overview annual publication from DMHAS

Avoiding the credibility mistakes. Several patterns undermine arguments:

1. Citing the most recent year’s data without the lag caveat. The current year is always incomplete; analysts who don’t acknowledge this look uninformed.
2. Using dashboard data to compare NJ to other states. State methodology differences make cross-state comparisons unreliable; use CDC WONDER for state-to-state.
3. Rounding numbers aggressively or providing figures without source attribution. Specific numbers with citations build credibility; vague “hundreds of deaths” framing undermines it.
4. Conflating suspected and confirmed death figures. Pick one stream and cite it clearly; don’t present suspected numbers as if they were confirmed.
5. Using absolute counts when per-capita rates matter, or vice versa. A small county with 40 deaths may be proportionally more affected than a large county with 200; a comparison that ignores population size is misleading.

The NJ data infrastructure is the best publicly accessible state-level overdose surveillance system in the region. Using it well — with methodological literacy and accurate citation — is what makes data-driven NJ advocacy defensible.

---

Frequently Asked Questions

Where can I find the NJ overdose dashboard? The NJ Department of Health publishes the overdose dashboard on its website. Search for “NJ overdose dashboard” or navigate through the NJ DOH site. The dashboard is publicly accessible and does not require a login.

What is SUDORS? SUDORS stands for State Unintentional Drug Overdose Reporting System. It is a CDC-funded surveillance program that collects detailed information on drug overdose deaths, including toxicology, circumstances, and treatment history. NJ participates in SUDORS, providing more granular data than standard vital statistics.

How often is the NJ overdose data updated? The dashboard is updated regularly, but the frequency varies. Suspected death data is reported in near-real-time, while confirmed data has a lag of weeks to months due to toxicology processing. SUDORS data has a longer lag of 12 to 18 months.

Which NJ counties have the highest overdose rates? Essex, Camden, Ocean, and Passaic counties have consistently reported among the highest overdose death totals. Per-capita rates vary and may be elevated in smaller counties with limited treatment access. The dashboard provides county-level detail for the most current available data.

---

This page is part of our Addiction Treatment Resources in New Jersey guide. For related content, see our pages on NJ addiction hotline resources and NJ rehabs under investigation. For statewide and national statistics, visit our NJ overdose data and opioid addiction NJ overdose data pages.